Literature DB >> 10214744

Outer retinal dysfunction in patients treated with vigabatrin.

C F Arndt1, P Derambure, S Defoort-Dhellemmes, J C Hache.   

Abstract

OBJECTIVE: To assess early visual impairment related to vigabatrin prospectively in patients with and without visual symptoms.
BACKGROUND: Vigabatrin acts as an inhibitor of gamma-aminobutyric acid (GABA) transaminase. GABA-induced ion transport changes in the retinal pigment epithelium have been described. The electro-oculogram (EOG) is a clinical test that reflects photoreceptor and pigment epithelium function. PATIENTS AND METHODS: Of the 22 consecutive patients presenting with a history of partial seizures currently treated with vigabatrin, 20 were included in the study. A complete clinical ophthalmologic and neurologic examination was performed, including static 100-point perimetry, EOG, and electroretinogram (ERG).
RESULTS: In 14 of 20 patients, the light/dark ratio (Arden ratio) of the standard EOG was reduced in at least one eye. The a- and b-wave amplitudes and implicit time of the ERG were within the normal range in all patients; however, ERG oscillatory potentials could not be recorded in 10 patients. Twelve patients had visual field constriction; five complained of visual symptoms. The most severe visual impairment was observed in patients treated with both vigabatrin and valproate.
CONCLUSIONS: There is some evidence of outer retinal dysfunction in the patients treated with vigabatrin. EOG, a more sensitive diagnostic tool than ERG for screening vigabatrin-treated patients, also appears to be more specific.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214744     DOI: 10.1212/wnl.52.6.1201

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Are vigabatrin-associated visual field constrictions asymptomatic?

Authors:  T Schmidt; K Rüther; B Schmitz
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

3.  Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG.

Authors:  Anja M Palmowski-Wolfe; Maria Timoner Perez; Stefanie Behnke; Gerhard Fuss; Martin Martziniak; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2006-06-22       Impact factor: 2.379

Review 4.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

5.  Vigabatrin associated retinal dysfunction in children with epilepsy.

Authors:  R Koul; A Chacko; A Ganesh; S Bulusu; K Al Riyami
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

Review 6.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

7.  Slow-stimulated multifocal ERG in high- and normal-tension glaucoma.

Authors:  Anja M Palmowski-Wolfe; Reiner J Allgayer; Bernhild Vernaleken; Andy Schötzau; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2006-06-19       Impact factor: 2.379

Review 8.  [Significance of GABAA receptors for the pathophysiology and therapy of panic disorders].

Authors:  R Rupprecht; P Zwanzger
Journal:  Nervenarzt       Date:  2003-06-24       Impact factor: 1.214

9.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

10.  Vigabatrin and visual field defects in pediatric epilepsy patients.

Authors:  Su Jeong You; HyoSook Ahn; Tae-Sung Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.